[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332486-105":59,"doc-detail-332486-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","evolving-molecular-subtyping-of-breast-cancer-advances-precision-treatment","Evolving molecular subtyping of breast cancer advances precision treatment","","Evolving molecular subtyping reshapes breast cancer taxonomy by using molecular profiling to define biologically distinct subtypes and enable precision systemic therapy. The editorial reviews progress from receptor-based classification (ER, PgR, HER2) and clinically relevant intrinsic subtypes to broader transcriptomic, surrogate, and integrative multi-omics strategies. It highlights how large-scale studies such as METABRIC and TCGA deepen understanding of heterogeneous tumor landscapes and support actionable clinical decision-making.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evolving-molecular-subtyping-of-breast-cancer-advances-precision-treatment/332486/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evolving-molecular-subtyping-of-breast-cancer-advances-precision-treatment/332486.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does molecular subtyping aim to address in breast cancer treatment?","Question",{"text":113,"@type":114},"Molecular subtyping clarifies the biological drivers of distinct breast cancer subtypes, enabling more precise diagnosis and selection of systemic therapies based on actionable oncogenic processes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are receptor-based subtypes commonly defined?",{"text":118,"@type":114},"Breast tumors are classified according to estrogen receptor (ER), progesterone receptor (PgR/PR), and HER2 status into HR-positive, HER2-positive, and triple-negative breast cancer subtypes, guiding endocrine, anti-HER2 targeted, or chemotherapy approaches.",{"name":120,"@type":111,"acceptedAnswer":121},"What role do transcriptomic and integrative profiling studies play?",{"text":122,"@type":114},"Transcriptomic profiling reveals intrinsic molecular complexity, while integrative analyses using datasets such as METABRIC and TCGA combine multiple genomic and transcriptomic layers to characterize heterogeneous tumor clusters and refine the molecular landscape.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},332486,1790013135,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Cancer Biol Med 2024. doi: 10.20892/j.issn.2095-3941.2024.0222  \nEDITORIAL  \nEvolving molecular subtyping of breast cancer advances precision treatment  \nRui Shan1,2*, Lei-Jie Dai1,2*, Zhi-Ming Shao1,2, Yi-Zhou Jiang1,2  \n1 Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China  \nBreast cancer is the second most prevalent cancer globally. In 2022, approximately 2.3 million newly diagnosed cases of female breast cancer occurred worldwide, and more than 665 thousand people lost their lives to this disease1.  \nUnderstanding of breast cancer began with clinical observations and pathological assessments. Various histologic types, sizes, nodal status, metastasis, grades, and stages predict different clinical outcomes and influence the selection of treatment options. In addition, molecular profiling offers another approach for classifying breast malignancies, thus enabling exploration of the biological factors underlying cancer development. Because each subtype is characterized by distinct oncogenic features that promote breast cancer onset and progression, targeting these biological processes has provided new opportunities for precision treatment. Consequently, molecular subtyping has become an integral and indispensable aspect of breast cancer taxonomy, and is critical in diagnosing breast cancer and determining subsequent precise systemic treatment.  \nThis editorial provides an overview of advancements in molecular subtyping for breast cancer with evolving molecular profiling methods, and ongoing efforts to integrate leading-edge subtyping concepts into precise clinical practice. We hope that this editorial will inspire researchers and medical professionals to recognize the importance of molecular classification and effectively apply these insights to clinical work.  \n*These authors contributed equally to this work. Correspondence to: Yi-Zhou Jiang  \n[E-mail: yizhoujiang@fudan.edu.cn](E-mail: yizhoujiang@fudan.edu.cn)  \nORCID ID: [https://orcid.org/0000-0003-3699-2630](https://orcid.org/0000-0003-3699-2630)  \n[Received June 17](Received June 17), 2024; accepted August 9, 2024. Available [at www.cancerbiomed.org](at www.cancerbiomed.org)  \n©2024 The Authors. Creative Commons Attribution-NonCommercial 4.0 International License  \nFrom receptor-based subtyping to comprehensive molecular subtyping of breast cancer  \nOn the basis of the status of the estrogen receptor (ER), progesterone receptor (PgR/PR), and human epithelial growth factor receptor 2 (HER2, also known as Erb-b2 receptor tyrosine kinase 2, ERBB2), breast tumors are generally classified into 3 receptor-based subtypes: hormone receptor (HR)-positive breast cancer, HER2-positive breast cancer, and triple-negative breast cancer (TNBC) . Patients with HR+ tumors should be treated with endocrine therapy, whereas patients with HER2+ tumors should receive targeted therapy with anti-HER2 agents2. However, the lack of feasible molecular targets has resulted in a preference for less specific chemotherapy as a systemic treatment option for TNBC2. Although the use of the traditional 3-class classification according to receptor status has increased patient survival over the past several decades, several challenges persist in enhancing patient prognosis3.  \nTo better determine the molecular landscape of breast cancer and identify potentially actionable targets, transcriptomic profiling was first used to systemically reveal the complexity of breast cancer. This technique provides a new perspective for stratifying patients beyond clinicopathological assessments, and enables the administration of treatment strategies with enhanced precision.  \nThe first systemic analysis of transcriptomic molecular subtypes was performed by Perou and colleagues4,5, who robustly constructed a clinically relevant classification system of intrinsic subtypes. After a decade, the","cbCaiedi9ZI3GyeD","https://ap.wps.com/l/cbCaiedi9ZI3GyeD","pdf",230848,"English","# From receptor-based subtyping to comprehensive molecular subtyping of breast cancer\n## Transcriptomic profiling and intrinsic subtype foundations\n## Surrogate molecular subtyping in clinical practice\n## Integrative analyses and multi-omics characterization","[{\"question\":\"What problem does molecular subtyping aim to address in breast cancer treatment?\",\"answer\":\"Molecular subtyping clarifies the biological drivers of distinct breast cancer subtypes, enabling more precise diagnosis and selection of systemic therapies based on actionable oncogenic processes.\"},{\"question\":\"How are receptor-based subtypes commonly defined?\",\"answer\":\"Breast tumors are classified according to estrogen receptor (ER), progesterone receptor (PgR/PR), and HER2 status into HR-positive, HER2-positive, and triple-negative breast cancer subtypes, guiding endocrine, anti-HER2 targeted, or chemotherapy approaches.\"},{\"question\":\"What role do transcriptomic and integrative profiling studies play?\",\"answer\":\"Transcriptomic profiling reveals intrinsic molecular complexity, while integrative analyses using datasets such as METABRIC and TCGA combine multiple genomic and transcriptomic layers to characterize heterogeneous tumor clusters and refine the molecular landscape.\"}]","Evolving molecular subtyping of breast cancer advances precision treatment | PDF",1789998433,23]